A5060010047- Anesthesia and Sedative Agents
- Epilepsy research and treatment
- Neuropeptides and Animal Physiology
- Pharmacogenetics and Drug Metabolism
- Pharmacological Effects and Toxicity Studies
- Cancer Treatment and Pharmacology
- Antibiotics Pharmacokinetics and Efficacy
- Intensive Care Unit Cognitive Disorders
- Receptor Mechanisms and Signaling
China National Pharmaceutical Group Corporation (China)
2024-2025
Princess Alexandra Hospital
2009
Abstract Ciprofol (HSK3486) is a newly developed, highly selective γ‐aminobutyric acid‐A (GABA A ) receptor potentiator that recently approved for new indication of sedation patients in the intensive care unit (ICU) China. This analysis aimed to characterize population pharmacokinetics (PopPKs) ciprofol and evaluate relationship exposure with hypotension mechanically ventilated ICU. total 462 subjects 3918 concentration measurements from two clinical trials ICU, four elective surgical...
Anrikefon (HSK21542), a potent and selective peripheral kappa opioid receptor (KOR) agonist developed by Haisco, effectively blocks pain itch signals. To develop population pharmacokinetic (PK) model for anrikefon conduct exposure-response (E-R) analysis safety efficacy in postoperative patients. The Population PK uses NONMEM software with data from six trials. E-R relationships were assessed using three Covariate screening Bayesian post-hoc simulations identified relevant factors compared...
The aim of this study was to elucidates the nuanced interactions between antihypertensive medications and risk periodontitis using Mendelian randomization (MR) analysis method.